Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000394897

Medchemexpress LLC SMI-4a | 438190-29-5 | 99.9% | 273.23 | 25 MG
SDP

Catalog No. 5000394897
Encompass_Preferred

SMI-4a (TCS-PIM-1-4a) is a potent, selective, cell-permeable, and ATP-competitive Pim-1 inhibitor with an IC50 of 24 μM and a Ki of 0.6 μM. It also inhibits Pim-2 (IC50 of 100 μM) but does not significantly inhibit other serine/threonine- or tyrosine-kinases. SMI-4a exhibits anticancer activity.

  • Potent, selective, cell-permeable, and ATP-competitive Pim-1 inhibitor.
  • Inhibits Pim-2.
  • Has anticancer activity.
  • Attenuates the autophosphorylation of tagged Pim-1 in intact cells at 0.5 μM.
  • Causes a dose-dependent reduction in Pim-1-induced 4E-BP1 phosphorylation, with an IC50 of approximately 125 nM in HEK-293T cells.

Catalog No. 50-003-94897 Supplier Medchemexpress LLC Supplier No. 25MGHY16576A
May include imposed supplier surcharges.
Add to Cart
Add to Cart

SMI-4a (TCS-PIM-1-4a) is a potent, selective, cell-permeable, and ATP-competitive Pim-1 inhibitor with an IC50 of 24 μM and a Ki of 0.6 μM. It also inhibits Pim-2 (IC50 of 100 μM) but does not significantly inhibit other serine/threonine- or tyrosine-kinases. SMI-4a exhibits anticancer activity.

  • Potent, selective, cell-permeable, and ATP-competitive Pim-1 inhibitor.
  • Inhibits Pim-2.
  • Has anticancer activity.
  • Attenuates the autophosphorylation of tagged Pim-1 in intact cells at 0.5 μM.
  • Causes a dose-dependent reduction in Pim-1-induced 4E-BP1 phosphorylation, with an IC50 of approximately 125 nM in HEK-293T cells.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.